ArticlePLoS medicine2018
Choices in vaccine trial design in epidemics of emerging infections.
Article in PLoS medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- Non-linear effects of age in reporting of adverse events following influenza immunization in Zhejiang, China.BMC infectious diseases · 2024Article
- Epidemiological contemplation for a currently pragmatic COVID-19 health passport: a perspective.Frontiers in public health · 2024Review
- The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks.Clinical trials (London, England) · 2022Article
- Response adaptive intervention allocation in stepped-wedge cluster randomized trials.Statistics in medicine · 2022Article
- Quantifying Efficiency Gains of Innovative Designs of Two-Arm Vaccine Trials for COVID-19 Using an Epidemic Simulation Model.Statistics in biopharmaceutical research · 2022Article
- Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.The Lancet. Infectious diseases · 2021Review
- Brief exposure of skin to near-infrared laser augments early vaccine responses.Nanophotonics (Berlin, Germany) · 2021Article
- Postmarketing Safety Monitoring After Influenza Vaccination Using a Mobile Health App: Prospective Longitudinal Feasibility Study.JMIR mHealth and uHealth · 2021Article
- Masks and distancing during COVID-19: a causal framework for imputing value to public-health interventions.Scientific reports · 2021Article
- Looking beyond COVID-19 vaccine phase 3 trials.Nature medicine · 2021Review
- On BCG Vaccine Protection from COVID-19: A Review.SN comprehensive clinical medicine · 2021Review
- Statistical Properties of Stepped Wedge Cluster-Randomized Trials in Infectious Disease Outbreaks.American journal of epidemiology · 2020Article
- Review
- Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.JMIR public health and surveillance · 2020Article
- Novel methods for the analysis of stepped wedge cluster randomized trials.Statistics in medicine · 2020Article
- Emerging Challenges and Opportunities in Infectious Disease Epidemiology.American journal of epidemiology · 2019Review
- How Modelling Can Enhance the Analysis of Imperfect Epidemic Data.Trends in parasitology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In a Policy Forum, Marc Lipsitch and colleagues discuss trial design issues in infectious disease outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.